{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:47:47Z","timestamp":1792784867309,"version":"4.5.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Numerous studies have demonstrated that Ashkenazi Jewish individuals heterozygous for\n                    <jats:italic>APC<\/jats:italic>\n                    c.3902T\u2009&gt;\u2009A; p.Ile1307Lys have 1.7-fold increased odds of colorectal adenocarcinoma (CRC). The cancer risk for homozygotes is unknown, and published data is based on small sample sizes. Here, we aim to quantitatively evaluate the odds of CRC in homozygotes from a clinical diagnostic setting. Analyses comparing the demographic and clinical histories among heterozygotes (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009340) or homozygotes (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200974) were compared to individuals with\n                    <jats:italic>MSH6<\/jats:italic>\n                    -associated Lynch syndrome (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009372) and individuals from a pan-cancer panel of up to 90 genes who were negative for\n                    <jats:italic>APC<\/jats:italic>\n                    I1307K,\n                    <jats:italic>MSH6<\/jats:italic>\n                    (likely) pathogenic (LP\/P) variants, and other reportable LP\/P variants after exclusions, henceforth referred to as wildtype (WT,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200919,809). Comparisons included Fisher\u2019s exact or two-sample t-test and multivariate logistic regression. Homozygotes demonstrated a trend toward increased odds of CRC compared to WT (OR: 2.48;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.074), and there was no difference between heterozygotes and WT (OR: 0.94;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.83).\n                    <jats:italic>MSH6<\/jats:italic>\n                    -positive individuals had increased odds of CRC relative to homozygotes (OR: 3.54;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.0001) but this was not significant in the logistic regression (OR: 1.19;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.78). While homozygotes but not heterozygotes demonstrated an increase in CRC OR compared to WT, there was no statistically distinct odds of CRC between heterozygotes and homozygotes in this cohort. While the ORs herein support that the observed increase in CRC for homozygotes was more modest than that observed for\n                    <jats:italic>MSH6<\/jats:italic>\n                    -related Lynch syndrome in this cohort, current sample size and selection bias limit precise risk estimation and do not allow for distinction between modestly increased risk and no risk of CRC.\n                  <\/jats:p>","DOI":"10.1007\/s10689-026-00600-0","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:23:10Z","timestamp":1789636990000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An update on APC I1307K homozygosity: observations from a large multigene panel testing cohort"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6522-4767","authenticated-orcid":false,"given":"Leah","family":"Zaretsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4626-4920","authenticated-orcid":false,"given":"Marcy E.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5186-6208","authenticated-orcid":false,"given":"Carrie","family":"Horton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3888-2239","authenticated-orcid":false,"given":"Magan","family":"Trottier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda M.","family":"Polfus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0341-4826","authenticated-orcid":false,"given":"Aimee L.","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"600_CR1","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3322\/caac.21772","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A (2023) Colorectal cancer statistics. CA Cancer J Clin 73:233\u2013254. https:\/\/doi.org\/10.3322\/caac.21772","journal-title":"CA Cancer J Clin"},{"key":"600_CR2","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/cncr.21230","volume":"104","author":"NP Zauber","year":"2005","unstructured":"Zauber NP, Sabbath-Solitare M, Marotta S, Zauber AG, Foulkes W, Chan M et al (2005) Clinical and genetic findings in an Ashkenazi Jewish population with colorectal neoplasms. Cancer 104:719\u2013729. https:\/\/doi.org\/10.1002\/cncr.21230","journal-title":"Cancer"},{"key":"600_CR3","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1001\/jama.284.7.857","volume":"284","author":"S Syngal","year":"2000","unstructured":"Syngal S, Schrag D, Falchuk M, Tung N, Farraye FA, Chung D et al (2000) Phenotypic characteristics associated with the APC gene I1307K mutation in Ashkenazi Jewish patients with colorectal polyps. JAMA 284:857\u2013860. https:\/\/doi.org\/10.1001\/jama.284.7.857","journal-title":"JAMA"},{"key":"600_CR4","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1136\/jmg-2022-108984","volume":"60","author":"L Valle","year":"2023","unstructured":"Valle L, Katz LH, Latchford A, Mur P, Moreno V, Frayling IM et al (2023) Position statement of the international society for gastrointestinal hereditary tumours (InSiGHT) on APC I1307K and cancer risk. J Med Genet 60:1035\u20131043. https:\/\/doi.org\/10.1136\/jmg-2022-108984","journal-title":"J Med Genet"},{"key":"600_CR5","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1136\/jmg-2025-110911","volume":"62","author":"A Allen","year":"2025","unstructured":"Allen A, Rowlands CF, Latchford A, Turnbull C, Valle L (2025) APC I1307K and clinical management: insights from UK Biobank association analysis of colorectal and other cancer risks in Ashkenazi and non-Ashkenazi whites. J Med Genet 62:767\u2013771. https:\/\/doi.org\/10.1136\/jmg-2025-110911","journal-title":"J Med Genet"},{"key":"600_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/1722","volume":"20","author":"T Woodage","year":"1998","unstructured":"Woodage T, King SM, Wacholder S, Hartge P, Struewing JP, McAdams M et al (1998) The APC I1307K allele and cancer risk in a community-based study of Ashkenazi Jews. Nat Genet 20:62\u201365. https:\/\/doi.org\/10.1038\/1722","journal-title":"Nat Genet"},{"key":"600_CR7","doi-asserted-by":"publisher","first-page":"3680","DOI":"10.1016\/j.ejca.2013.06.040","volume":"49","author":"B Boursi","year":"2013","unstructured":"Boursi B, Sella T, Liberman E, Shapira S, David M, Kazanov D et al (2013) The APC p.I1307K polymorphism is a significant risk factor for CRC in average risk Ashkenazi Jews. Eur J Cancer 49:3680\u20133685. https:\/\/doi.org\/10.1016\/j.ejca.2013.06.040","journal-title":"Eur J Cancer"},{"key":"600_CR8","unstructured":"National Comprehensive Cancer Network NCCN Guidelines: genetic\/familial high-risk assessment: colorectal, endometrial, esophageal, and gastric [Internet]. Version 1.2026 [cited 2026 June 28]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_ceeg.pdf"},{"key":"600_CR9","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1001\/jama.2021.6238","volume":"325","author":"US Preventive Services Task Force","year":"2021","unstructured":"US Preventive Services Task Force (2021) Screening for colorectal cancer: US preventive services task force recommendation statement. JAMA 325:1965\u20131977. https:\/\/doi.org\/10.1001\/jama.2021.6238","journal-title":"JAMA"},{"key":"600_CR10","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3322\/caac.21457","volume":"68","author":"AMD Wolf","year":"2018","unstructured":"Wolf AMD, Fontham ETH, Church TR, Flowers CR, Guerra CE, LaMonte SJ et al (2018) Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA: A Cancer J Clin. 68:250\u2013281. https:\/\/doi.org\/10.3322\/caac.21457","journal-title":"CA: A Cancer J Clin"},{"issue":"2","key":"600_CR11","doi-asserted-by":"publisher","first-page":"100992","DOI":"10.1016\/j.gim.2023.100992","volume":"26","author":"I Spier","year":"2023","unstructured":"Spier I, Yin X, Richardson M, Pineda M, Laner A, Ritter D et al (2023) Gene-specific ACMG\/AMP classification criteria for germline APC variants: recommendations from the ClinGen InSiGHT hereditary colorectal cancer\/polyposis variant curation expert panel. Genet Med 26(2):100992. https:\/\/doi.org\/10.1016\/j.gim.2023.100992","journal-title":"Genet Med"},{"key":"600_CR12","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1159\/000518683","volume":"14","author":"A Rosenblum","year":"2021","unstructured":"Rosenblum A, Springer M, Eppolito A, Axell L, Mohler L (2021) Homozygous Germline APC p.I1307K variants: a case series. Case Rep Oncol 14:1295\u20131303. https:\/\/doi.org\/10.1159\/000518683","journal-title":"Case Rep Oncol"},{"key":"600_CR13","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1080\/02841860701716900","volume":"47","author":"P Zauber","year":"2018","unstructured":"Zauber P, Sabbath-Solitare M, Stephen PM, Chamberlain R, Chong G, Foulkes WD et al (2018) Sporadic desmoid tumor in an Ashkenazi patient homozygous for the APC*I1307K gene mutation. Acta Oncol 47:1158\u20131161. https:\/\/doi.org\/10.1080\/02841860701716900","journal-title":"Acta Oncol"},{"key":"600_CR14","unstructured":"CancerNext-Expanded [Internet]. California: Ambry Genetics [cited 2026 January 25]. Available from: https:\/\/www.ambrygen.com\/providers\/genetic-testing\/28\/oncology\/cancernext-expanded"},{"issue":"5","key":"600_CR15","doi-asserted-by":"publisher","first-page":"pkaa027","DOI":"10.1093\/jncics\/pkaa027","volume":"4","author":"C Wang","year":"2020","unstructured":"Wang C, Wang Y, Hughes KS, Parmigiani G, Braun D (2020) Penetrance of colorectal cancer among mismatch repair gene mutation carriers: a meta-analysis. JNCI Cancer Spectr 4(5):pkaa027. https:\/\/doi.org\/10.1093\/jncics\/pkaa027","journal-title":"JNCI Cancer Spectr"},{"key":"600_CR16","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41436-019-0633-8","volume":"22","author":"H LaDuca","year":"2020","unstructured":"LaDuca H, Polley EC, Yussuf A, Hoang L, Gutierrez S, Hart SN et al (2020) A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients. Genet Med 22:407\u2013415. https:\/\/doi.org\/10.1038\/s41436-019-0633-8","journal-title":"Genet Med"}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-026-00600-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10689-026-00600-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-026-00600-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:02:08Z","timestamp":1792782128000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10689-026-00600-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":16,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["600"],"URL":"https:\/\/doi.org\/10.1007\/s10689-026-00600-0","relation":{},"ISSN":["1573-7292"],"issn-type":[{"value":"1573-7292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"15 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Supplementary file has been updated.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MER, TC, CH, MT, and LMP are employees of Ambry Genetics and may be equity shareholders in Tempus AI.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"WCG Institutional Review Board determined the study to be exempt from the Office for Human Research Protections Regulations for the Protection of Human Subjects (45 CFR 46) under category 4. Retrospective data analysis of de-identified data exempted the study from the requirement to receive consent from patients.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"89"}}